00

Hunan Hansen Pharmaceutical Co LtdSHE 002412 Stock Report

Last reporting period 30 Sep, 2023

Updated 18 Sep, 2024

Last price

Market cap $B

0.352

Micro

Exchange

XSHE - Shenzhen Stock Exchange

002412.SZ Stock Analysis

00

Neutral

Based on Eyestock quantitative analysis, 002412.SZ`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

68/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

41.1 %

Greatly undervalued

Market cap $B

0.352

Dividend yield

4.39 %

Shares outstanding

503.2 B

Hunan Hansen Pharmaceutical Co. Ltd. engages in the research, development, manufacture, and sale of Chinese medicines. The company is headquartered in Yiyang, Hunan and currently employs 1,532 full-time employees. The company went IPO on 2010-05-25. The Company’s main products include Simotang oral liquid, used for abdominal distention and phlegmatic abdominalgia; Yushangling capsules, used for injuries from falls; Yinxingye capsules, used for stroke and chest distress, as well as Suoquan capsules, used for kidney deficiency, among others. The firm mainly distributes its products in domestic markets.

View Section: Eyestock Rating